CA15-3, CEA and CA27.29 was found to have increased sensitivity in metastatic BC (Hou et al. 1999) and to be useful in monitoring response to therapy with serial measurements (Seale and Tkaczuk 2022). Here, CEACAM5 is linked to breast cancer.